Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) each utilizes four bases in a particular sequence to form genetic information. DNA uses adenine [A], guanine [G], thymine [T], and cytosine [C], while RNA uses A, G, C and Uracil (U). In both DNA and RNA, these bases are attached to a sugar-phosphate backbone having a 3′ end and an opposing 5′ end. When two single strands of DNA bind (associate) to form double-stranded DNA (hybridized or duplexed DNA), the 5′ to 3′ direction in one strand is positioned in a complementary manner, e.g., 180 degrees relative to the 5′ to 3′ direction of the other strand. A is complementary to T and G is complementary to C in DNA/DNA hybrids. A is complementary to U and G is complementary to C in DNA/RNA hybrids.
Amplification reactions are used to increase the number of DNA and/or RNA so that detection of specific sequences can be achieved. In certain types of amplification reactions, a relatively short sequence of DNA called a primer associates with a complementary sequence on the DNA template. A DNA polymerase uses deoxynucleoside triphosphates (dNTPs) to sequentially add nucleotides to the 3′ end of the primer (also referred to herein as “extension”). For extension to occur, a 3′ hydroxyl group is required on the ribose ring, which is the sugar moiety of the nucleic acid backbone. If the 3′ hydroxyl group of a nucleotide is replaced with a hydrogen atom, the nucleotide is known as a dideoxynucleotide (ddNTP), and cannot support attachment of an additional base during extension.
One of the drawbacks of certain amplification reactions is creation of “negative reaction products”. These negative reaction products have been found to be the result of the forward and reverse primers combining with one another to varying degrees in a template independent fashion. Although the precise mechanism for generation of this negative reaction product is not completely known, it is understood that certain reactions occur involving the primers in a forward-forward, forward-reverse or reverse-reverse configuration. These reactions can generate negative reaction products that can interfere with the accuracy of the detection process.
The present invention is directed to a method for amplification and capture of nucleic acid sequences. In one embodiment, the method includes one or more of the steps of annealing a forward primer to a DNA or RNA template using fewer than four different dNTPs; extending the forward primer with the dNTPs to form an extended primer that terminates when an omitted dNTP is required for further extension of the forward primer; releasing the extended primer; exponentially amplifying the extended primer, adding a reverse primer, four different dNTPs and a capture probe, the capture probe including n oligonucleotides, wherein fewer than n of the oligonucleotides are locking nucleic acids; and concurrently capturing one of the extended primers in the reaction vessel with the capture probe while amplifying the extended primer. Further, in certain embodiments, the steps of annealing, extending and releasing occur at a first reaction temperature that is substantially isothermal and in the absence of a helicase. In addition, or alternatively, the steps of exponentially amplifying and capturing occur at a second reaction temperature that is substantially isothermal.
In certain embodiments, the steps of annealing, extending and releasing are all performed in a non-exponential manner. In one embodiment, the step of annealing includes the forward primer having approximately 11 bases. In another embodiment, the step of extending includes the extended primer having approximately 22 bases. The step of annealing can include using one ddNTP and three dNTPs that are different from one another.
In one specific embodiment, the number of bases of the capture probe (n) equals 16. Further, in one embodiment, the number of locking nucleic acids can be less than approximately 75% of n. In some embodiments, n can be greater than approximately 14 and less than approximately 18. In these and other embodiments, the number of locking nucleic acids can be greater than approximately 6 and less than approximately 12. Further, at least one of the reaction temperatures can be within the range of between approximately 60° C. and 68° C. In one specific embodiment, the reaction temperature is approximately 65° C. In certain embodiments, the first reaction temperature can be substantially similar to the second reaction temperature.
The novel features of this invention, as well as the invention itself, both as to its structure and its operation, will be best understood from the accompanying drawings, taken in conjunction with the accompanying description, in which similar reference characters refer to similar parts, and in which:
In certain embodiments, the amplification and capture method includes a linear or otherwise non-exponential initiation process (indicated as steps 1-4, also sometimes referred to herein as a linear amplification phase) and a subsequent exponential amplification/capture process (indicated as steps 5-6, also sometimes referred to herein as an exponential amplification phase). As illustrated in
In the embodiment illustrated in
In the embodiment illustrated in
In this example, a mixture of known amounts of each of the following are combined: the DNA (or RNA) template, the 11mer primer, a polymerase and the nucleotides complementary only to the “A”, “C” and “G” (thus, only “T”, “G” and “C”, respectively, and no “A”). In one embodiment, during an isothermal process at a given temperature, e.g., 65° C. or another suitable temperature, the 11mer temporarily binds to the template as illustrated in
In an alternative embodiment, using the above example, in addition to excluding base “A” from the reaction mixture, a dideoxynucleotide for “A” (also known as “ddATP”) can be added to the reaction mixture. In this embodiment, the ddATP cannot be extended from, and the extension reaction is terminated. It is understood that depending upon the base sequence of the DNA or RNA template, one or more dideoxynucleotides (ddATP, ddTTP, ddCTP and/or ddGTP) can be included in the reaction mixture to achieve the desired termination effect.
It is recognized that although the number of bases of certain nucleotides is sometimes specified herein (i.e. 11mer, 22mer, etc.) during various methods and processes, this specificity is provided as a representative example only, and is not intended to limit the nucleotides that can be utilized with the present invention in any manner to any particular number of bases.
Referring back to
In one embodiment, the capture probes can directly or indirectly be attached to magnetic beads (indicated as an “M” in a circle), as one non-exclusive example. In the embodiment illustrated in
In this example, at 65° C. (other suitable temperatures can be used), the double stranded 22mer becomes denatured, and the desired single-stranded target can bind to the capture probe. In certain embodiments, the capture probes can include one or more locked nucleic acids (LNA's). One example of a more detailed explanation of LNA's can be found in publications known to those skilled in the art, including, but not limited to “Locked Nucleic Acids (LNA) (Ørum, H., Jakobsen, M. H., Koch, T., Vuust, J. and Borre, M. B. (1999) Detection of the Factor V Leiden Mutation by Direct Allele-specific Hybridization of PCR Amplicons to Photoimmobilized Locked Nucleic Acids. Clin Chem., 45:1898-1905)”, the publication of which is incorporated herein by reference to the extent permitted.
In some embodiments, the number and/or positioning of the LNA's can influence the melting temperature of the capture probe. Depending upon the melting temperature of the capture probe relative to the melting temperature of the DNA or RNA product, an isothermal process at a predetermined temperature can occur that allows both denaturing of the double stranded product and capture of the desired strand by the capture probe at substantially the same time, in the same reaction vessel. In certain embodiments, the capture probe includes a sufficient number of locking nucleic acids to allow efficient capture of the reaction products from the isothermal amplification reaction without requiring a separate denaturing step. As illustrated in
In certain embodiments, the reaction temperature is set high enough so that the labeled 11mer primers (such as 5′ (biotin marker) CATTCTGGAA A 3′ in
Alternatively, or in addition, the sequence of the capture probe is predetermined to generate a relatively low binding energy so that the 11mer primers are inhibited from binding with the capture probe in the first instance. In contrast, when the 22mer reaction product binds to the capture probe, sufficient homology exists to cause a greater level of binding energy. This increased binding energy ultimately generates a bead signal that can be readily detected by methods known to those skilled in the art.
The number of LNA's in the capture probe is adequate enough to allow efficient hybridization to occur at the elevated reaction temperature used for the isothermal amplification reaction. Alternatively, other types of modified nucleotide analogs (e.g PNA's) can be used to increase the binding energy of the capture probes above the isothermal reaction temperature.
In certain embodiments, by including the magnetic capture beads with attached capture probes in the reaction mixture during isothermal amplification, generation of the negative reaction products is inhibited.
However, in
In an alternative embodiment, capture probes that are specific to the negative reaction product(s) can be utilized to effectively suppress proliferation of the negative reaction products. These capture probes that target the negative reaction products are also referred to herein as “suppression probes”. The suppression probes can be added either during or after the isothermal amplification process. Therefore, one or more different suppression probes can be used to specifically target and capture the different negative reaction products that may be formed during isothermal amplification before these negative reaction products can exponentially amplify. With this design, a smaller amount of negative reaction product will be generated, thus yielding a more accurate detection of the actual nucleic acid sequences present.
Thus, in certain embodiments, a preferred temperature of the reaction is at or near the Tm of the capture probe. Further, in some embodiments, the temperature used during the described method is greater than the Tm of the DNA or RNA product (such as the previously described 22mer reaction product), which in this example is approximately 50° C. Therefore, by adjusting the number of LNA's relative to the number of nucleotides in the capture probe, and setting the appropriate temperature of the mixture, capturing efficiency can be increased and/or optimized.
In one embodiment of the capture probe, at least 12 nucleotides are included. In non-exclusive alternative embodiments, at least 10, but not greater than 20 nucleotides are included in the capture probe. Still alternatively, the capture probe can include fewer than 10 or greater than 20 nucleotides. Further, in certain embodiments, less than approximately 75% of the nucleotides in the capture probe are locking nucleic acids. In non-exclusive alternative embodiments, less than approximately 90%, 62.5%, 50%, 40% or 25% of the nucleotides in the capture probe are locking nucleic acids. In other embodiments, at least 6, but not greater than 12 locking nucleic acids are included in the capture probe. In still alternative embodiments, fewer than 6 or greater than 12 locking nucleic acids can be included in the capture probe.
While the particular methods and compositions for amplification and/or capturing of nucleic acid sequences as shown and disclosed herein are fully capable of obtaining the objects and providing the advantages herein before stated, it is to be understood that it is merely illustrative of the presently preferred embodiments of the invention and that no limitations are intended to the details of the methods, construction or design herein shown and described.
This Application claims domestic priority on U.S. Provisional Application Ser. No. 60/832,049, filed on Jul. 20, 2006, and on U.S. Provisional Application Ser. No. 60/921,796, filed on Apr. 4, 2007. The contents of U.S. Provisional Application Ser. Nos. 60/832,049 and 60/921,796 are incorporated herein by reference to the extent permitted.
Number | Name | Date | Kind |
---|---|---|---|
4994368 | Goodman et al. | Feb 1991 | A |
5011769 | Duck et al. | Apr 1991 | A |
5112734 | Kramer et al. | May 1992 | A |
5270184 | Walker et al. | Dec 1993 | A |
5273879 | Goodman et al. | Dec 1993 | A |
5356774 | Axelrod et al. | Oct 1994 | A |
5397698 | Goodman et al. | Mar 1995 | A |
5418149 | Gelfand et al. | May 1995 | A |
5471676 | Muraishi | Nov 1995 | A |
5591609 | Auerbach | Jan 1997 | A |
5648211 | Fraiser et al. | Jul 1997 | A |
5674679 | Fuller | Oct 1997 | A |
5712124 | Walker | Jan 1998 | A |
5741640 | Fuller | Apr 1998 | A |
5744311 | Fraiser et al. | Apr 1998 | A |
5756285 | Fuller | May 1998 | A |
5814492 | Carrino et al. | Sep 1998 | A |
5824517 | Cleuziat et al. | Oct 1998 | A |
5908744 | McAllister et al. | Jun 1999 | A |
6033881 | Himmler et al. | Mar 2000 | A |
6087133 | Dattagupta et al. | Jul 2000 | A |
6124120 | Lizardi | Sep 2000 | A |
6143495 | Lizardi | Nov 2000 | A |
6180338 | Adams | Jan 2001 | B1 |
6207368 | Adams | Mar 2001 | B1 |
6214587 | Dattagupta et al. | Apr 2001 | B1 |
6225062 | Dunn et al. | May 2001 | B1 |
6225067 | Rogers | May 2001 | B1 |
6248567 | Liles et al. | Jun 2001 | B1 |
6251639 | Kurn | Jun 2001 | B1 |
6255082 | Lizardi | Jul 2001 | B1 |
6261808 | Auerbach | Jul 2001 | B1 |
6280949 | Lizardi | Aug 2001 | B1 |
6642034 | Lizardi | Nov 2003 | B2 |
6686156 | Kurn | Feb 2004 | B2 |
6692918 | Kurn | Feb 2004 | B2 |
6716580 | Gold et al. | Apr 2004 | B2 |
6821734 | Kambara et al. | Nov 2004 | B2 |
6825010 | Spier et al. | Nov 2004 | B2 |
6972174 | Xue et al. | Dec 2005 | B2 |
RE38960 | Dattagupta et al. | Jan 2006 | E |
6994963 | Murphy et al. | Feb 2006 | B1 |
RE39007 | Dattagupta et al. | Mar 2006 | E |
7074600 | Dean et al. | Jul 2006 | B2 |
20010036629 | Dower et al. | Nov 2001 | A1 |
20020058270 | Kurn | May 2002 | A1 |
20020137036 | Sorge et al. | Sep 2002 | A1 |
20020187477 | Xue et al. | Dec 2002 | A1 |
20030017487 | Xue et al. | Jan 2003 | A1 |
20030044779 | Goelet et al. | Mar 2003 | A1 |
20030082572 | Spier et al. | May 2003 | A1 |
20030087271 | Ebersole et al. | May 2003 | A1 |
20030104430 | Nerenberg et al. | Jun 2003 | A1 |
20030104431 | Van Ness et al. | Jun 2003 | A1 |
20030143536 | Lizardi | Jul 2003 | A1 |
20030143587 | Dean et al. | Jul 2003 | A1 |
20030190627 | Zhao et al. | Oct 2003 | A1 |
20030207292 | Notomi et al. | Nov 2003 | A1 |
20040038258 | Harley et al. | Feb 2004 | A1 |
20040063144 | Lizardi et al. | Apr 2004 | A1 |
20040175729 | Hiyama | Sep 2004 | A1 |
20040203019 | Kurn | Oct 2004 | A1 |
20040203025 | Kurn | Oct 2004 | A1 |
20040234996 | Hanna | Nov 2004 | A1 |
20040248105 | Kumar | Dec 2004 | A1 |
20050095610 | Kuo et al. | May 2005 | A1 |
20050164213 | Tabor et al. | Jul 2005 | A1 |
20050239109 | Hurt | Oct 2005 | A1 |
20050260573 | Rabbani et al. | Nov 2005 | A1 |
20060084068 | Johnson | Apr 2006 | A1 |
20060099607 | Nakashima et al. | May 2006 | A1 |
20060115838 | Bazar et al. | Jun 2006 | A1 |
20060160084 | Mitani et al. | Jul 2006 | A1 |
20060160108 | Romanov et al. | Jul 2006 | A1 |
20060166250 | Brenner | Jul 2006 | A1 |
20060172333 | Chen | Aug 2006 | A1 |
Number | Date | Country |
---|---|---|
0300796 | Jan 1989 | EP |
0826779 | Mar 1998 | EP |
0971039 | Jan 2000 | EP |
1275715 | Jan 2003 | EP |
10066589 | Mar 1998 | JP |
WO-9014439 | Nov 1990 | WO |
WO-9101384 | Feb 1991 | WO |
WO-9104340 | Apr 1991 | WO |
WO-9201813 | Feb 1992 | WO |
WO-9503430 | Feb 1995 | WO |
WO-9525180 | Sep 1995 | WO |
WO-9617079 | Jun 1996 | WO |
WO-9623904 | Aug 1996 | WO |
WO9727331 | Jul 1997 | WO |
WO-9811255 | Mar 1998 | WO |
WO-9918241 | Apr 1998 | WO |
WO-9838296 | Sep 1998 | WO |
WO-0028084 | May 2000 | WO |
WO-0041524 | Jul 2000 | WO |
WO-0041524 | Jul 2000 | WO |
WO-0062036 | Oct 2000 | WO |
WO-0070095 | Nov 2000 | WO |
WO-0070095 | Nov 2000 | WO |
WO0120035 | Mar 2001 | WO |
WO-0246456 | Jun 2002 | WO |
WO-02061145 | Aug 2002 | WO |
WO-03008642 | Jan 2003 | WO |
WO-03008642 | Jan 2003 | WO |
WO-03054233 | Jul 2003 | WO |
WO-03080645 | Oct 2003 | WO |
WO-03093500 | Nov 2003 | WO |
WO-2004027025 | Apr 2004 | WO |
WO-2004055197 | Jul 2004 | WO |
WO-2004058987 | Jul 2004 | WO |
WO-2004058987 | Jul 2004 | WO |
WO-2004063700 | Jul 2004 | WO |
WO-2005016251 | Feb 2005 | WO |
WO-2005016251 | Feb 2005 | WO |
WO-2005030929 | Apr 2005 | WO |
WO-2005030983 | Apr 2005 | WO |
WO-2005047462 | May 2005 | WO |
WO-2005089508 | Sep 2005 | WO |
WO-2005118853 | Dec 2005 | WO |
WO-2005118853 | Dec 2005 | WO |
WO-2005123961 | Dec 2005 | WO |
WO-2005123961 | Dec 2005 | WO |
WO-2006026388 | Mar 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20080171364 A1 | Jul 2008 | US |
Number | Date | Country | |
---|---|---|---|
60832049 | Jul 2006 | US | |
60921796 | Apr 2007 | US |